


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9009822/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e498.	6.0	81
2	Learning from Nature: Pregnancy Changes the Expression of Inflammation-Related Genes in Patients with Multiple Sclerosis. PLoS ONE, 2010, 5, e8962.	2.5	69
3	Aquaporin-4 antibody titration in NMO patients treated with rituximab. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e317.	6.0	53
4	Anti-interferon-β neutralising activity is not entirely mediated by antibodies. Journal of Neuroimmunology, 2007, 192, 198-205.	2.3	22
5	Evaluation of a Multiparametric Immunofluorescence Assay for Standardization of Neuromyelitis Optica Serology. PLoS ONE, 2012, 7, e38896.	2.5	19
6	Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice. Multiple Sclerosis and Related Disorders, 2021, 54, 103090.	2.0	13
7	Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients. Journal of Immunological Methods, 2017, 445, 53-58.	1.4	10
8	CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study. Journal of Neuroimmunology, 2014, 277, 127-133.	2.3	5
9	Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-Î ³ and interleukin-4 response. Multiple Sclerosis Journal, 2012, 18, 1484-1492.	3.0	2
10	Quality control in biobank samples: The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes. Journal of the Neurological Sciences, 2021, 429, 119937.	0.6	0